Stocks › ASND
Ascendis Pharma A/S
ASND·Nasdaq·USD
$226.05
-1.98 (-0.87%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ASND
Ascendis Pharma A/S · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ASNDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ASND by members of U.S. Congress · 3 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Gary J. PalmerHouse · R · AL |
ASNDAscendis Pharma A/S · Stock |
Sale $1,001 - $15,000 |
Nov 7, 2018 | Oct 5, 2018 | Filing ↗ |
| Gary J. PalmerHouse · R · AL |
ASNDAscendis Pharma A/S · Stock |
Purchase $1,001 - $15,000 |
Sep 29, 2018 | Aug 6, 2018 | Filing ↗ |
| Gary J. PalmerHouse · R · AL |
ASNDAscendis Pharma A/S · Stock |
Purchase $1,001 - $15,000 |
Sep 29, 2018 | Jul 12, 2018 | Filing ↗ |
Whale Activity
Position changes in ASND reported for 2026-06-30 by 21 tracked institutional filers
- Increased0
- New8
- Held0
- Decreased0
- Closed6
- No prior filing7
| Filer | Shares | Value | Change |
|---|---|---|---|
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4.8M | $1.28B | — |
| Artisan Partners Limited Partnership | 2.6M | $702.5M | — |
| BlackRock, Inc. | 2.2M | $589.9M | new |
| TWO SIGMA INVESTMENTS, LP | 305.8K | $81.6M | new |
| MILLENNIUM MANAGEMENT LLC | 266.7K | $71.1M | new |
| CITADEL ADVISORS LLC | 137.9K | $36.8M | new |
| BRAUN STACEY ASSOCIATES INC | 132.7K | $35.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | 119.7K | $31.9M | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 103.5K | $27.6M | new |
| Atika Capital Management LLC | 61.0K | $16.3M | — |
| D. E. Shaw & Co., Inc. | 30.9K | $8.2M | new |
| Seven Fleet Capital Management LP | 11.9K | $3.2M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ASND insiders, by quarter · Form 4
Recent Insider Transactions
12 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Bodenhoff MadsSVP & PAO | Sale | −3,000 | $270.19 | $811K | Sep 8, 2026 | Form 4 ↗ |
| HOLTUG LARSDirector · Director | Sale | −236 | $264.13 | $62K | Sep 2, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector · Director | Purchase | +900 | $246.91 | $222K | Aug 14, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector · Director | Purchase | +1,100 | $245.85 | $270K | Aug 14, 2026 | Form 4 ↗ |
| SMITH SCOTT THOMASEVP & Chief Financial Officer | Purchase | +100 | $219.00 | $22K | Jun 2, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +100 | $223.50 | $22K | May 29, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $222.30 | $44K | May 29, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $223.76 | $45K | May 29, 2026 | Form 4 ↗ |
| SMITH SCOTT THOMASEVP & Chief Financial Officer | Purchase | +250 | $223.32 | $56K | May 29, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $239.37 | $48K | May 26, 2026 | Form 4 ↗ |
| BIENAIME JEAN JACQUESDirector | Purchase | +200 | $236.24 | $47K | May 26, 2026 | Form 4 ↗ |
| JENSEN FLEMMING STEENSee Remarks | Sale | −19.5K | $238.49 | $4.6M | May 11, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ASND · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund T. Rowe Price Capital Appreciation Fund, Inc. | 2.7M | $626.9M | 0.95% | Mar 31, 2026 |
| Franklin Dynatech Fund Franklin Custodian Funds | 1.1M | $251.6M | 1.02% | Mar 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 783.4K | $179.2M | 0.80% | Mar 31, 2026 |
| Artisan Mid Cap Fund ARTISAN PARTNERS FUNDS INC | 678.3K | $155.2M | 5.25% | Mar 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 676.2K | $154.7M | 1.42% | Mar 31, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund JNL SERIES TRUST | 603.3K | $138.0M | 1.00% | Mar 31, 2026 |
| SMALLCAP World Fund Inc | 579.2K | $132.5M | 0.16% | Mar 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust | 547.4K | $125.2M | 1.36% | Mar 31, 2026 |
| New Perspective Fund | 463.4K | $106.0M | 0.07% | Mar 31, 2026 |
| Janus Henderson Enterprise Fund JANUS INVESTMENT FUND | 455.0K | $104.1M | 0.51% | Mar 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ASND's shares (CUSIP 04351P101), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Artisan Partners Limited PartnershipSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - Artisan Investments GP LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - Artisan Partners Holdings LPSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - Artisan Partners Asset Management Inc.SCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
Aug 13, 2026 · ↗ - JANUS HENDERSON GROUP PLCSCHEDULE 13G/A · passive (13G) · 3.7M shares6.0%
May 15, 2026 · ↗ - Capital International InvestorsSCHEDULE 13G/A · passive (13G) · 2.0M shares3.2%
May 14, 2026 · ↗ - T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 6.5M shares10.5%
May 7, 2026 · ↗ - T. Rowe Price Investment Management, Inc.SCHEDULE 13G · passive (13G) · 6.2M shares9.9%
May 7, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 3.9M shares6.6%
May 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 3.9M shares6.6%
May 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Ascendis Pharma A/S as client
No lobbying filings found naming Ascendis Pharma A/S as the client.
Government Contracts
Federal awards to Ascendis Pharma A/S · USAspending
No federal contract awards found for Ascendis Pharma A/S.
U.S. Patents
Recent USPTO applications naming Ascendis Pharma A/S
No USPTO patent applications found for Ascendis Pharma A/S.
Annual Financials
From ASND's 10-K filings · XBRL
No annual XBRL figures on record for ASND. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ASND's price history.
Material Events (8-K)
Corporate events filed with the SEC
No 8-K filings on record.
About Ascendis Pharma A/S
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersHELLERUP
IncorporatedG7
SEC CIK0001612042 ↗